GYRE insider buying and SEC filings, explained
Gyre Therapeutics, Inc. · CIK 1124105
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- CATALYST BIOSCIENCES, INC.; TARGACEPT INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$83K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 5–6, 2026 | Planned (10b5-1) | Ying Luo (CEO and Director) sold 10,315 shares indirectly (by spouse) between May 5 and May 6 at about $8.04 ($83K), marked as a 10b5-1 plan trade. Holdings by spouse down <1% to 2,565,226 shares. | SEC filing Filed May 7, 2026 |
31 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow GYRE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.